Tag: Drug development
Study: Altimmune Obesity Drug for Alcohol Use Disorder Research
Boston's biotech sector is facing challenges, with companies struggling amid a slump in the industry. Despite hopes for a turnaround in 2025, falling stock values, layoffs, and excess lab space have left the region...
Next-Gen Obesity Drug Disappoints: Novo Nordisk Shares Drop
Novo Nordisk, a pharmaceutical giant, recently experienced a setback that sent shockwaves through the industry. The company's highly anticipated next-generation obesity drug, CagriSema, failed to meet investors' expectations, resulting in a significant drop in...
Bill in Congress to Eliminate Small vs Large Molecule Drug Distinctions
In a recent development in Congress, lawmakers have put forth a bill aimed at amending a crucial aspect of the Inflation Reduction Act due to concerns that the current law is hindering investments in...
FDA Pauses Study on Amgen’s Obesity Treatment
The Food and Drug Administration (FDA) recently put a hold on Amgen's study of their early-stage obesity treatment, known as AMG 513, marking a potential setback for the company in the competitive weight loss...
